
Enrolment concludes in Belite Bio’s trial of Tinlarebant for geographic atrophy
Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral Tinlarebant in individuals with geographic atrophy (GA) in dry age-related macular degeneration (AMD). This multicentre, randomised, …